The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time

BACKGROUND: Breast cancer is a heterogeneous disease with overexpression of several receptors, such as human epidermal receptor 2 (HER2), which is a prognostic and predictive biomarker for treatment with the anti-HER2 monoclonal antibody trastuzumab. This study aimed to test the contribution of this...

Descripción completa

Detalles Bibliográficos
Autores principales: da Luz, Felipe Andrés Cordero, da Costa Marinho, Eduarda, Nascimento, Camila Piqui, de Andrade Marques, Lara, Delfino, Patrícia Ferreira Ribeiro, Antonioli, Rafael Mathias, Silva, Marcelo José Barbosa, de Araújo, Rogério Agenor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831111/
https://www.ncbi.nlm.nih.gov/pubmed/35242228
http://dx.doi.org/10.3332/ecancer.2022.1347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831111/
https://www.ncbi.nlm.nih.gov/pubmed/35242228
http://dx.doi.org/10.3332/ecancer.2022.1347

Ejemplares similares